News
01-05-2011, 01:31 AM
Alnylam Pharmaceuticals, a leading RNAi therapeutics company, today presented new clinical data from its ALN-VSP Phase I liver cancer trial in a presentation at the Dana-Farber Cancer Institute in Boston. Results from molecular analysis of human biopsy samples showed achievement of pharmacologically relevant siRNA drug levels in tissues.
More... (http://www.news-medical.net/news/20110105/Alnylam-presents-ALN-VSP-Phase-I-trial-results-for-liver-cancer.aspx)
More... (http://www.news-medical.net/news/20110105/Alnylam-presents-ALN-VSP-Phase-I-trial-results-for-liver-cancer.aspx)